Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
YL-202 by Suzhou Medilink Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
YL-202 is under clinical development by Suzhou Medilink Therapeutics and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According...